Xceleron has developed a series of drug development solutions that enable its clients to make better decisions on new drugs, faster and at a fraction of the expense incurred by drug companies traditionally.
Xceleron's approach unlocks the potential of drug pipelines in clinical drug development through the application of ground breaking ultra-sensitive analytical techniques that generate early insight into human drug interactions.
The Company is recognized as the global leader in its field and is a proven partner to a range of over 100 pharma-biotech businesses, both private and public.
19 January 2010
Frog Capital Backs Continued Expansion of Xceleron28 April 2009
Xceleron Launches Solution to FDA MIST16 December 2008
Global Leader in Predictive Clinical Research Names Michael Butler as President & CEO05 June 2007
Xceleron and Sanofi-Aventis Sign Deal to Address Challenges in Exploratory Clinical DevelopmentFrog are professional investors in the best sense, experienced at managing and communicating expectations, addressing potential ambiguities and helping the company develop.
Ian Buckley-Goulder, Chairman
.jpg)
